Dr. Charles S. Plimpton, MD
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
350 W Thomas Rd
Phoenix, AZ 85013
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
AZ license 20429
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Medical groups
- Women's Care Arizona, LLC (35 clinicians)
- Obhg Arizona PC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Progesterone (progesterone, micronized) Other prescribers in Phoenix, AZ | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $63.56 in total to this clinician.
| Hologic Sales and Service, LLC | $22.45 |
|---|---|
| Evofem Biosciences, Inc. | $21.77 |
| Optumhealth Care Solutions, LLC | $19.34 |
| Food and Beverage | $63.56 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $280,141 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease
Merck Sharp & Dohme LLC - Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Sanofi Pasteur Inc. · Active, not recruiting · NCT06686654 - A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
ModernaTX, Inc. · Completed · NCT06634797 - Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2)
ModernaTX, Inc. - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A phase 1/2, randomized, observer-blinded, multi-country study to eval
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.